Selecky Christobel's Form 4 filing
ImmunityBio, Inc. (IBRX) · filed Jul 1, 2026
- Accession no.
- 0001849739-26-000011
- Filed
- Jul 1, 2026, 5:04 PM ET
- Trade date
- Jun 29-30, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 5 derivative transactions. Open-market sales total $871.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Selecky ChristobelCIK 0001849739 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Common Stock | MOption exerciseAcquired | +32,173 | $2.98 | +$95,875.54 | 32,173 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseAcquired | +33,549 | $2.99 | +$100,311.51 | 65,722 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseAcquired | +30,000 | $2.84 | +$85,200 | 95,722 | Direct | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −95,722 | $9.01F2 | −$862,215.92 | 0 | Direct | |
| Jun 30, 2026 | Common Stock | MOption exerciseAcquired | +700 | $2.98 | +$2,086 | 700 | Direct | |
| Jun 30, 2026 | Common Stock | MOption exerciseAcquired | +300 | $2.99 | +$897 | 1,000 | Direct | |
| Jun 30, 2026 | Common Stock | SSaleDisposed | −1,000 | $9.00 | −$9,000 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Common Stock | MOption exerciseDisposed | −32,173 | $0.00 | $0 | 35,764 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseDisposed | −33,549 | $0.00 | $0 | 124,714 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseDisposed | −30,000 | $0.00 | $0 | 132,786 | Direct | |
| Jun 30, 2026 | Common Stock | MOption exerciseDisposed | −700 | $0.00 | $0 | 35,064 | Direct | |
| Jun 30, 2026 | Common Stock | MOption exerciseDisposed | −300 | $0.00 | $0 | 124,414 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average share price of an aggregate total of 95,722 shares sold in the price range of $9.00 to $9.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.